To scroll text in this page

Global Navigation

Social Responsibility

Start of the main text

Participation in Global Health Innovative Technology Fund (GHIT Fund)

Astellas participates in the Global Health Innovative Technology Fund (GHIT Fund), a product development fund for global health R&D which is built on the strength of contributions from partners in the public, private, and civil sectors, to support the research and development of drugs, vaccines, diagnostics and other products for HIV/AIDS, Malaria, Tuberculosis, and other NTDs needed by the poorest of the poor in developing nations.

GHIT Fund Joint Press Conference at TICAD-V Side event
image of GHIT Fund Joint Press Conference at TICAD-V Side event
From the left, Kiyoshi Kurokawa (Representative Director and Chairman of the GHIT Fund), BT Slingsby (Executive Director and CEO of the GHIT Fund), Masafumi Nogimori (Representative Director and Chairman of the Board of Astellas Pharma Inc.), Joji Nakayama (President and CEO of Daiichi Sankyo Co., Ltd.), Trevor Mundel (President of Global Health at the Bill & Melinda Gates Foundation), Haruo Naito (President and CEO of Eisai Co., Ltd.), Isao Teshirogi (President and CEO of Shionogi & Co., Ltd), Yasuchika Hasegawa (President and CEO of Takeda Pharmaceutical Company Limited.), Shinichi Iida (Director, Global Issues Cooperation Division, International Cooperation Bureau, Ministry of Foreign Affairs), Kazushi Yamauchi (Director, International Cooperation Office, International Affairs Division, Minister's Secretariat, Ministry of Health, Labour and Welfare)
[As of 2013.6.1]


Main Text end
Local Navigation
Local Navigation end
Related Links